Eledon Pharmaceuticals, Inc.

NASDAQ•ELDN

CEO: Dr. David-Alexandre C. Gros M.D., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-09-17

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Contact Information

19900 MacArthur Boulevard, Suite 550, Irvine, CA, 92612, United States

949-238-8090

eledon.com

Market Cap

$163.06M

P/E (TTM)

-2.7

17.5

Dividend Yield

52W High

$4.60

52W Low

$1.35

52W Range

42%

Rank48Top 64.4%

3.3

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 3.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.23-121.55%

4-Quarter Trend

FCF

-$14.48M+23.01%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

R&D Spending Increased Research and development expenses rose $14.74M to $48.78M for nine months ended September 30, 2025, supporting clinical trials.

Warrant Liability Decreased Fair value of warrant liabilities fell $22.92M to $21.95M, reflecting stock price decline and recognized as income.

Recent Financing Secured Successfully closed November 2025 offering, raising approximately $53.6M in net proceeds to fund future operations and development.

Net Loss Widened Nine months net loss reached $35.17M, reversing prior period's $8.43M net income due to operational costs.

Risk Factors

Continued Operating Losses Expect recurring net losses for several years; requires substantial additional capital to fund ongoing research and development activities.

Clinical Development Uncertainty Product candidates are in early stages; failure to successfully develop or gain approval will materially harm business prospects.

Significant Stock Dilution Need for future capital raises via equity or debt risks significant dilution to existing common stockholders' ownership interests.

Material Weakness Persists Disclosure controls and procedures were not effective due to an unresolved material weakness in internal control over financial reporting.

Outlook

Kidney Program Prioritization Strategy focuses on advancing tegoprubart for kidney transplant rejection; ALS development requires specific additional financing to continue.

Cash Runway Projection Current cash resources are estimated sufficient to meet anticipated cash needs for at least the next 12 months.

Seek Additional Capital Anticipates needing additional financing beyond 12 months via equity, debt, or strategic collaborations to fund future operations.

Advance Regulatory Filings Plans to continue clinical development, manufacturing scale-up, and seek marketing approval for product candidates in key indications.

Peer Comparison

Revenue (TTM)

PBYI

$228.42M

-0.9%

VNDA

$216.11M

+8.7%

EDIT

$40.52M

+25.4%

Gross Margin (Latest Quarter)

APLT

100.0%

+0.0pp

EDIT

96.7%

+2621.3pp

VNDA

93.3%

+0.1pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ALLO	$555.08M	-2.8	-57.1%	18.0%
VNDA	$549.11M	-2.5	-49.2%	2.6%
TRDA	$496.93M	-3.9	-39.8%	13.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 19, 2026

EPS:-$0.20

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data